breast cancer, genomics, adjuvant treatment, clinical trial
Key words: breast cancer, triple-negative breast cancer, real-world data, ESME cohort, overall survival, ESME cohort
metastatic breast cancer, Real-world evidence, HER2-low, HR-positive, trastuzumab deruxtecan